Immunotherapy of hepatocellular carcinoma: is there a place for regulatory T-lymphocyte depletion?
| Autor: | Vanessa Gauttier, Jeannette Cany, Jean-Paul Judor, Nicolas Ferry, Sophie Conchon, Lucile Tran, Georges Vassaux |
|---|---|
| Rok vydání: | 2011 |
| Předmět: |
Carcinoma
Hepatocellular medicine.medical_treatment Immunology Genetic Vectors Immunotherapy Adoptive T-Lymphocytes Regulatory Lymphocyte Depletion Mice Immune system Antigen Antigens Neoplasm medicine Carcinoma Immunology and Allergy Animals Humans Diethylnitrosamine IL-2 receptor Immune Regulation Translational research [NCMLS 2] biology business.industry Liver Neoplasms Antibodies Monoclonal Immunotherapy medicine.disease digestive system diseases Tumor Burden Oncology Immunization Hepatocellular carcinoma biology.protein Antibody business |
| Zdroj: | Immunotherapy, 3, 4 Suppl, pp. 32-4 Immunotherapy, 3, 32-4 |
| ISSN: | 1750-743X |
| Popis: | Item does not contain fulltext Immunotherapy represents a potential therapeutic option for patients with hepatocellular carcinoma (HCC), especially as secondary treatment to prevent recurrence. It has been shown that a patient's survival is directly correlated to the type and number of tumor-infiltrating immune cells, indicating that immune responses have a direct effect on the clinical course of the disease. We have assessed the potential of immunotherapy against HCC in preclinical models of low tumor burden. An antigen-specific strategy targeting alpha-fetoprotein, and consisting of immunization with a DNA-based synthetic vector (DNAmAFP/704), was tested on an autochthonous model of chemical hepatocarcinogenesis and led to an important (65%) reduction of the tumor burden. A nonspecific approach of CD25(+) T-cell depletion by injection of PC61 antibody was also tested on an orthotopic HCC model and led to a significant protection against tumor development. Antigen-specific immunotherapy and Treg depletion are promising strategies in physiologically relevant HCC preclinical models. Future clinical trials will demonstrate if a combination of Treg depletion with an antigen-specific immunotherapy will also translate into clinical responses in HCC patients. 01 april 2011 |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|